Related Experiment Video

Updated: Jan 28, 2026

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

18.7K

Factors Affecting Pediatric Dyslipidemia Screening and Treatment

Lisa Herrington1, Apryl Susi2, Gregory Gorman2,3

  • 11 Naval Medical Center San Diego, San Diego, CA, USA.

Clinical Pediatrics
|February 23, 2019
PubMed

Insights

Pediatric dyslipidemia screening remains low, with only 6.6% of children evaluated. Conditions like parental dyslipidemia and diabetes increased screening odds, but overall rates need improvement to reduce future cardiovascular risk.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Risk Management
  • Public Health

Background:

  • Dyslipidemia in childhood is a significant risk factor for future cardiovascular disease.
  • Early identification and management are crucial for mitigating long-term health consequences.
  • Current screening and treatment practices in pediatric populations require evaluation.

Purpose of the Study:

  • To assess the factors influencing the screening and treatment of pediatric dyslipidemia.
  • To evaluate adherence to the 2011 National Heart, Lung, and Blood Institute (NHLBI) guidelines.
  • To identify predictors for screening, elevated low-density lipoprotein cholesterol (LDL-C), and pharmacotherapy.

Main Methods:

  • Retrospective cohort study of 1,736,032 children aged 2-18 years (2009-2013).
  • Logistic regression analysis to determine factors affecting screening, elevated LDL-C, and treatment.
  • Analysis based on NHLBI-identified risk factors.

Main Results:

  • Only 6.6% of children were screened for dyslipidemia.
  • Screening rates increased in 9-11 year olds from 2009-2012.
  • 16.5% of screened children had elevated LDL-C; 2.3% received pharmacotherapy.
  • Parental dyslipidemia, diabetes, chronic kidney disease, and other specific conditions increased screening odds.
  • Older age, nephrotic syndrome, chronic kidney disease, diabetes, and hypertension increased odds for elevated LDL-C and treatment.

Conclusions:

  • Pediatric dyslipidemia screening rates remain low despite established guidelines.
  • Certain comorbidities significantly increase the likelihood of screening and treatment.
  • Further efforts are needed to improve early detection and management of pediatric dyslipidemia.

Keywords:
cholesteroldyslipidemiaguidelinespediatricscreening

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.6K
Guidelines for Elective Pediatric Fiberoptic Intubation11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.5K

Related Concept Videos

Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
225
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
285
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
213
Factors Affecting Solubility04:01

Factors Affecting Solubility

Compared with pure water, the solubility of an ionic compound is less in aqueous solutions containing a common ion (one also produced by dissolution of the ionic compound). This is an example of a phenomenon known as the common ion effect, which is a consequence of the law of mass action that may be explained using Le Chȃtelier’s principle. Consider the dissolution of silver iodide:
37.0K
Transcription Elongation Factors02:35

Transcription Elongation Factors

Transcription elongation is a dynamic process that alters depending upon the sequence heterogeneity of the DNA being transcribed. Hence, it is not surprising that the elongation complex's composition also varies along the way while transcribing a gene.
The transcription elongation is regulated via pausing of RNA polymerase on several occasions during transcription. In bacteria, these halts are necessary because the transcription of DNA into mRNA is coupled to the translation of that mRNA...
13.8K